諾和諾德與美國生物技術公司合作開發肥胖症藥物Novo Nordisk, U.S. Biotech Company Team Up to Create Obesity Pills

動脈網

2025/05/17

FRIDAY, May 16, 2025 — Danish drugmaker2025年5月16日，星期五——丹麥製藥商Novo Nordisk諾和諾德is teaming up with California-based biotech Septerna to develop new pills to treat obesity,正在與加利福尼亞州的生物技術公司 Septerna 合作，開發治療...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2536494313"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536494313\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536494313?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-05-17 01:49","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2536494313","market":"us","top_or_hot":-1,"title":"諾和諾德與美國生物技術公司合作開發肥胖症藥物Novo Nordisk, U.S. Biotech Company Team Up to Create Obesity Pills","media":"動脈網","content":"<div>\n<p>FRIDAY, May 16, 2025 — Danish drugmaker2025年5月16日，星期五——丹麥製藥商Novo Nordisk諾和諾德is teaming up with California-based biotech Septerna to develop new pills to treat obesity,正在與加利福尼亞州的生物技術公司 Septerna 合作，開發治療...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250517015016975c016e&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>諾和諾德與美國生物技術公司合作開發肥胖症藥物Novo Nordisk, U.S. Biotech Company Team Up to Create Obesity Pills</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n諾和諾德與美國生物技術公司合作開發肥胖症藥物Novo Nordisk, U.S. Biotech Company Team Up to Create Obesity Pills\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">動脈網</strong><span class=\"h-time small\">2025-05-17 01:49</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>FRIDAY, May 16, 2025 — Danish drugmaker2025年5月16日，星期五——丹麥製藥商Novo Nordisk諾和諾德is teaming up with California-based biotech Septerna to develop new pills to treat obesity,正在與加利福尼亞州的生物技術公司 Septerna 合作，開發治療...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250517015016975c016e&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250517015016975c016e&s=b\">動脈網</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250517015016975c016e&s=b","article_id":"2536494313","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250517015016975c016e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2536494313","pubTimestamp":1747417740,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"The deal could be worth up to $2.2 billion for這筆交易的價值可能高達22億美元Septerna七重奏. This includes more than $200 million in upfront and short-term milestone payments, plus future rewards tied to research, development and sales. Septerna will also get royalties on any future product sales,這包括超過2億美元的預付款和短期里程碑付款，以及與研發和銷售相關的未來獎勵。Novo Nordisk will pay all the research and development costs for the project.諾和諾德將支付該項目的所有研發費用。Eli Lilly公司流行的減肥藥Zepbound澤普綁定targets both GLP-1 and another GPCR called GIP.同時靶向GLP-1和另一個名為GIP的GPCR。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","NVO":"诺和诺德","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4585":"ETF&股票定投概念","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4588":"碎股","BK4532":"文艺复兴科技持仓","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4599":"减肥药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)"},"translate_title":"Novo Nordisk partners with US biotech firm to develop obesity drug Novo Nordisk, U.S. Biotech Company Team Up to Create Obesity Pills","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"FRIDAY, May 16, 2025 — Danish drugmaker2025年5月16日，星期五——丹麥製藥商Novo Nordisk諾和諾德is teaming up with California-based biotech Septerna to develop new pills to treat obesity,正在與加利福尼亞州的生物技術公司 Septerna 合作，開發治療肥胖症的新藥片，type 2 diabetes2型糖尿病and other metabolic diseases.和其他代謝性疾病。The deal could be worth up to $2.2 billion for這筆交易的價值可能高達22億美元Septerna七重奏. This includes more than $200 million in upfront and short-term milestone payments, plus future rewards tied to research, development and sales. Septerna will also get royalties on any future product sales,這包括超過2億美元的預付款和短期里程碑付款，以及與研發和銷售相關的未來獎勵。Septerna還將獲得任何未來產品銷售的特許權使用費。The Wall Street Journal《華爾街日報》reported.據報道。Novo Nordisk will pay all the research and development costs for the project.諾和諾德將支付該項目的所有研發費用。The U.S. biotech company has developed a platform that finds and develops drugs that target special proteins called G protein-coupled receptors (GPCRs).美國生物技術公司已經開發了一個平台，可以尋找和開發針對特殊蛋白質——G蛋白偶聯受體（GPCRs）的藥物。These proteins help pass chemicals from outside cells to the inside. Many major drugs on the market today also target GPCRs.這些蛋白質幫助將細胞外的化學物質傳遞到細胞內。當今市場上的許多主要藥物也針對GPCRs。Novo Nordisk’s best-known drug,諾和諾德最著名的藥物，Wegovy諾和盈, targets a GPCR called GLP-1. Eli Lilly’s popular weight-loss drug，針對一種名為GLP-1的GPCR。Eli Lilly公司流行的減肥藥Zepbound澤普綁定targets both GLP-1 and another GPCR called GIP.同時靶向GLP-1和另一個名為GIP的GPCR。「Septerna has demonstrated strong capabilities in GPCR drug discovery,'「Septerna在GPCR藥物發現方面展現了強大的能力，」Marcus Schindler馬庫斯·辛德勒, chief scientific officer at Novo Nordisk, told諾和諾德的首席科學官告訴The Wall Street Journal.《華爾街日報》。「We are excited about the opportunity to develop oral small molecule medicines directed at multiple targets,」 he added.「我們對開發針對多個靶點的口服小分子藥物的機會感到興奮，」他補充道。The two companies plan four programs to create pills that target GPCRs including GLP-1, GIP and glucagon — which are important proteins involved in blood sugar and appetite control,兩家公司計劃開展四個項目，以研發針對GPCR的藥丸，包括GLP-1、GIP和胰高血糖素——這些是參與血糖和食慾控制的重要蛋白質。The WSJ《華爾街日報》said.説。Right now, leading weight-loss drugs must be injected into the body. Pill versions could make the drugs more convenient for patients and easier to ship and store.目前，主流的減肥藥物必須通過注射進入體內。藥丸版本可能會讓患者使用起來更方便，也更容易運輸和儲存。About one-third of drugs approved by the U.S. Food and Drug Administration (FDA) target GPCRs, according to Novo Nordisk. But an estimated 75% of GPCR targets have not yet been used in medicine, meaning there’s still a big opportunity for discovery.根據諾和諾德的數據，約三分之一的美國食品藥品監督管理局（FDA）批准的藥物針對的是GPCR，但據估計，75%的GPCR靶點尚未在醫學中使用，這意味着仍有很大的發現機會。Septerna’s stock jumped 69% in premarket trading after the deal was announced. Novo Nordisk’s stock rose 1.2% in European trading.Septerna的股票在交易宣佈後，盤前交易中上漲了69%。諾和諾德的股票在歐洲交易中上漲了1.2%。Whatever your topic of interest,無論你感興趣的話題是什麼，subscribe to our newsletters訂閲我們的新聞通訊to get the best of Drugs.com in your inbox.獲取 Drugs.com 的最佳內容到您的收件箱。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}